Introduction
Perioperative management of IBD therapies, particularly advanced therapies (AT), in patients undergoing non–IBD-related surgery remains uncertain because of limited evidence and lack of clear guidelines. While continuing treatment may increase postoperative infectious risk through immunosuppression, interruption may trigger disease flares and corticosteroid use, potentially increasing complications.
Aims & Methods
This study aimed to evaluate the impact of perioperative AT exposure on postoperative complications following non–IBD-related surgery, with a focus on continuation versus interruption of AT. We conducted a retrospective multicentre cohort study including adult patients with IBD who underwent planned non–IBD-related surgery between 2014 and 2025. The most common surgeries in patients with IBD were selected, regardless of IBD treatment or perioperative management, with at least 6 months of follow-up. The primary outcome was any postoperative complication. Secondary outcomes included surgical site infection, medical infection, sepsis, thromboembolic events, bleeding, IBD flare, reoperation, readmission, and mortality. Univariate and multivariate analyses identified factors associated with overall complications, infectious complications, and IBD flare. To evaluate the impact of perioperative AT, patients were classified into three groups: no AT, continuation, or interruption (missing at least one scheduled dose prior to surgery, based on the interval between the last administration and the surgical procedure).
Results
A total of 208 surgeries were performed in 186 patients (57.5% female; 71% CD; median age 54): 102 with no AT (49.0%), 89 with AT continuation (42.8%), and 17 with AT interruption (8.2%). At the time of surgery, AT included anti-TNF in 43, anti-integrins in 30, anti-IL in 22, and JAK inhibitors in 11. The most common procedures were ophthalmic (18.3%), orthopedic (17.8%), gastrointestinal (15.4%), gynecological (12.0%), neurosurgical (11.1%), urological (10.1%) and others (15.3%). Overall, 43 surgeries (20.7%) were associated with complications, most commonly IBD flare (6.7% of all surgeries), medical infection (4.8%), surgical site infection (4.8%), bleeding (3.4%), readmission (2.9%), reoperation (2.9%), venous thromboembolism (1%), sepsis (0.5%), and mortality (0.5%). Most complications occurred within 30 days (62.8%), mainly infections, bleeding, and thromboembolic events, whereas IBD flares were more evenly distributed over time. In univariate analysis, interruption of AT (OR 4.39, 95% CI 1.46–13.2; p=0.027) and opioid use (OR 6.60, 95% CI 3.03–14.4; p<0.001) were associated with complications. In multivariate analysis, higher Charlson comorbidity index (OR 1.22, 95% CI 1.02–1.45; p=0.027) and opioid use (OR 6.5, 95% CI 2.82–15.1; p<0.0001) were independent predictors. For infectious complications, perianal disease was inversely associated with risk (OR 0.115, 95% CI 0.02–0.90; p=0.039), while opioid use remained a risk factor (OR 3.3, 95% CI 1.20–9.04; p=0.021). For IBD flare, interruption of AT was associated with an approximately ninefold higher risk (OR 8.8, 95% CI 1.8–44.0; p=0.024), and opioid use was also associated (OR 5.57, 95% CI 1.51–20.6; p=0.010). Results were consistent after adjustment for age, BMI, smoking, and corticosteroid use. No specific therapeutic class was independently associated with overall postoperative or infectious complications.
Conclusion
Perioperative interruption of advanced IBD therapy was associated with increased postoperative complications, particularly IBD flares, without clear reduction in infectious risk.